Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Verona Pharma plc is a biopharmaceutical company specializing in developing and commercializing inhaled respiratory therapies. Its flagship product, Ohtuvayre (ensifentrine), is a first-in-class inhaled dual PDE3 and PDE4 inhibitor approved for COPD maintenance treatment. The company focuses on innovative treatments targeting unmet needs in respiratory diseases, leveraging strategic partnerships and a strong patent portfolio to expand into global markets.
This description was generated via AI from an annual report. Updated about 1 year ago.